{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:42Z","timestamp":1788952482818,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Functional high\u2010risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS) &lt;2 years. The optimal definition of FHR in the era of combined quadruplet therapy (QUAD)\u00a0+\u00a0autologous stem cell transplantation (ASCT) is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors analyzed 310 patients with newly diagnosed MM who received QUAD\u00a0+\u00a0ASCT and had with a median follow up of 41.8 months, with 66 progression events, to identify the optimal definition of FHR MM and to explore the factors associated with outcomes of subsequent therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative incidence of progression with FHR cutoff points of within 12 months (FHR12), 18 months (FHR18), 24 months (FHR24), and 36 months (FHR36) of treatment initiation were 2.6%, 6.2%, 10.1%, and 16.4%, respectively. The median second PFS (2PFS) and OS from the onset of second\u2010line therapy were 3.0 and 8.1 months, respectively, for FHR12; 2.7 and 8.1 months, respectively, for FHR18; 3.3 and 15.7 months, respectively, for FHR24; and 5.8 and 23.8 months, respectively, for FHR36, pointing to 36 months as the optimal cutoff point to define FHR MM. The 12\u2010month 2PFS rate was 80% versus 23% for patients treated with versus without T\u2010cell\u2013redirecting therapy, respectively. In multivariable analysis, T\u2010cell\u2013redirecting therapy was associated with a substantially improved 2PFS even when adjusted for FHR status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the current era of QUAD\u00a0+\u00a0ASCT, the definition of FHR MM should encompass patients who have MM with disease progression in the first 36 months of therapy. This study provides benchmark data for clinical trials deploying agents with novel mechanisms of action in this difficult\u2010to\u2010treat population (ClinicalTrtials.gov identifier NCT03224507).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70478","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:01:28Z","timestamp":1784530888000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining functional high\u2010risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation"],"prefix":"10.1002","volume":"132","author":[{"given":"Gayathri","family":"Ravi","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Medicine Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"Division of Hematology, Medical Oncology and Palliative Care Department of Medicine University of Wisconsin  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Medvedova","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai R.","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology Department of Medicine Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly N.","family":"Godby","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest","family":"Huls","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Silbermann","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Medicine Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240966"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.331"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236588"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16793"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010129431"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100057\u20105"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.014"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.10.009"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.43"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.05.111"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.147"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010204365"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00217\u2010X"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00236\u20103"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010177546"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00282\u20101"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201024\u201002266"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201001893"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001030\u2010w"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201021\u20100134"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201007\u2010038430"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.8545"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010199550"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7504"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30452\u20106"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70002"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002404\u20106"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100435\u20107"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70478","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:38:46Z","timestamp":1788950326000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1002\/cncr.70478"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70478","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2025-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70478"}}